Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.058%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Chief executives and the itch to quit

Thu, 16th May 2013 10:28

By Andrew Callus

LONDON, May 16 (Reuters) - On approaching his 60th birthdaythis year, long-serving Tullow Oil boss Aidan Heaveytold staff he felt "like two 30 year-olds".

A handful of recent shock departures by 50-something chiefexecutives at European blue chip companies - none of them underany obvious pressure to quit - suggest some of his peers eitherlack that vigour, or want to channel it elsewhere.

Peter Voser is giving up one of the world's most challengingCEO roles at Royal Dutch/Shell next year, before his55th birthday, in pursuit of a "lifestyle change".

Swiss engineering group ABB's 55-year old boss Joe Hogan is also going, for "private reasons". Pierre-OlivierBeckers, 53, is walking out on Belgian retailer Delhaize, and Paul Walsh, 57, is waving goodbye to drinksmultinational Diageo.

All four are about average European CEO age.

Luxury goods group Richemont's chairman and founderJohann Rupert, older, at 62, than the rest of the May retirees,gave up the CEO post in April and on Thursday announced he wouldtake a year off from the chairmanship, too, to catch up on somereading. And perhaps a trip to the Antarctic.

While the rising financial rewards of running a modernmultinational have been well publicised, executive recruiterssay the pressures of the job have also been ratcheted up inrecent years, and not just because of the tough economic times.

"The reality is it's gruelling. It's really tough, and therecomes a point where you don't want to do it any more," said IanButcher, who headhunts board-level and senior executives for MWMConsulting.

"The quarterly reporting, the governance, the regulatoryaspects, it just becomes very wearing - the level of scrutiny,the pace at which things are moving, the short-term nature ofhow people look at any given situation. Even over the past fiveyears these things have made CEO a tougher position to hold, andthe travel that people have to undertake in these jobs - it'sjust something they run out of steam on."

"I just want to be master of my time for some time," saidRichemont's Rupert.

Some recent early retirees, while still well short oftraditional retirement age, got to the top spot early.

"They're still in their early fifties, with energy and adesire to do something, but they want to do something different,something quite significantly different sometimes," saysButcher.

Voser might not be donning snow shoes for an Antarcticventure, but he has no plans to collect well-paid chairmanshipsand non-executive directorships, as many ex-CEOs have done inthe past. Former Tesco chief Terry Leahy has alsoresisted that gravy train since he left two years ago.

As for the early starters, executive search industryprofessionals point at people like Andrew Witty, the CEO ofGlaxoSmithKline, who took on the job aged 44 in 2008 andwould have to stay in harness for another decade to reach 60 inthe role.

Blue-chip bosses as young as Witty are still rare, but overa quarter of Europe's current crop have less than two years inthe job, and more than half have less than four, according todata from executive search specialists BoardEx.

MEDIAN CEO AGE IS 55 YEARS

The BoardEx data, collected for Reuters from 238 companiesin the main stock indexes of Germany, Britain, France, Spain,Italy, Belgium, the Netherlands and Denmark, puts the median CEOage at 55, and the median tenure at four years. Only 16 percentof the group have held on for 10 years and more. ()

The longest serving of them is Martin Gilbert of the Britishfund Aberdeen Asset Management. Though younger, at 57,Gilbert pips the 28.3-year tenure of Tullow's double thirtyyear-old Heavey, with 29.8 years at the helm.

There are 17 top European CEOs who have been in the job forless than six months, and the youngest of the 225 in the groupfor whom ages were available is Vitaly Nesis, 37, who runsPolymetal International, the London-listed Russianprecious metals miner.

While the recent spate of quitters are looking for somethingelse to do, there are still some who appear to want nothing but.

In the BoardEx group there are four over 70, and the oldestby eight years is Albert Frere, CEO of Group Bruxelles Lambert.

Perhaps some linger on for fear that the pension pot isstill a little light. Frere will have put such qualms behind himlong ago. At 87, he is Belgium's richest man.

More News
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more
4 Jan 2024 14:01

UK dividends calendar - next 7 days

Friday 5 January 
British Land Co PLCdividend payment date
Hill & Smith PLCdividend payment date
JD Sports Fashion PLCdividend payment date
JPMorgan Global Growth & Income PLCdividend payment date
Liontrust Asset Management PLCdividend payment date
Lok'n Store Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
RS Group PLCdividend payment date
Tate & Lyle PLCdividend payment date
Monday 8 January 
abrdn Equity Income Trust PLCdividend payment date
Intermediate Capital Group PLCdividend payment date
Tuesday 9 January 
no events scheduled 
Wednesday 10 January 
Assura PLCdividend payment date
Bellway PLCdividend payment date
Fidelity Special Values PLCdividend payment date
LXi REIT PLCdividend payment date
Severn Trent PLCdividend payment date
Volex PLCdividend payment date
Vp PLCdividend payment date
Thursday 11 January 
AJ Bell PLCex-dividend payment date
Ashtead Group PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
CMC Markets PLCdividend payment date
dotdigital Group PLCex-dividend payment date
Ecora Resources PLCex-dividend payment date
European Assets Trust PLCex-dividend payment date
Foresight Group Holdings Ltdex-dividend payment date
GSK PLCdividend payment date
ICG-Longbow Senior Secured UK Property Debt Investments Ltdex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
Keystone Positive Change Investment Trust PLCex-dividend payment date
LondonMetric Property PLCdividend payment date
Murray International Trust PLCex-dividend payment date
National Grid PLCdividend payment date
Primary Health Properties PLCex-dividend payment date
Sage Group PLCex-dividend payment date
Smiths News PLCex-dividend payment date
SSE PLCex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
TR Property Investment Trust PLCdividend payment date
Walker Crips Group PLCex-dividend payment date
WH Smith PLCex-dividend payment date
Worldwide Healthcare Trust PLCdividend payment date
XPS Pensions Group PLCex-dividend payment date
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.